Novartis AG (NOVN) Gets a Buy from Kepler Capital
Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on April 2 and set a price target of CHF135.00. The company’s shares closed last Thursday at CHF123.20.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Evans is ranked #5966 out of 12068 analysts.
In addition to Kepler Capital , Novartis AG also received a Buy from Bank of America Securities’s Sachin Jain in a report issued on March 30. However, on March 31, Goldman Sachs maintained a Sell rating on Novartis AG (Six Swiss: NOVN).
Based on Novartis AG’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of CHF13.44 billion and a net profit of CHF2.43 billion. In comparison, last year the company earned a revenue of CHF13.56 billion and had a net profit of CHF2.82 billion
Read More on CH:NOVN:
Disclaimer & DisclosureReport an Issue
- White House says imposing tariffs on patented pharmaceutical products
- Trump Trade: President says Iran war will still take weeks
- Trump administration readying new pharmaceutical tariffs, FT reports
- Trump Trade: U.S. not pulling assets from Strait of Hormuz yet
- Drugmakers delay drug launch in Europe over U.S. pricing policies, Reuters says
